Figure S2 Overview of the data flow and analyses. Schematic representation of the concept of the project and of the steps in the analysis. (TIF) Figure S3 Analysi-es of p53 endogenous expression in wild type and deficient p53 tumors. A. Schematic representation of the primer design for the specific detection of the endogenous p53 transcript. B. Expression of endogenous p53 in TH-MYCN and TH-MYCN/p53ERTAM tumors. The samples from p53 wild type mice (n = 5) express approximately 2-fold more endogenous p53 (p,0.001) compared to TH-MYCN/p53ERTAM tumors (n = 6). (TIF) Figure S4 Comparison between miRNAs differentially expressed in human and mouse neuroblastoma tumors. A. Schematic representation of the clearing process for comparing the lists becoming from studies on different species. B. Venn diagram representing the overlapping of miRNAs deregulated in human and mice neuroblastoma. miRNAs differentially expressed in mouse tumors compared to adrenals (pink circle), miRNAs deregulated in human MNA compared to non-MNA in Bray (purple circle) and miRNAs differentially expressed in human MNA compared to non-MNA Mestdagh (green circle). (TIF) References 1. Stallings RL (2007) Are chromosomal imbalances important in cancer? Trends Genet 23: 278–283. 2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121–1124. 3. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, et al. (2009) Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One 4: e8154. 4. Murphy DM, Buckley PG, Bryan K, Watters KM, Koster J, et al. (2011) Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog 50: 403–411. 5. Westermann F, Muth D, Benner A, Bauer T, Henrich KO, et al. (2008) Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol 9: R150. 6. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522–531. 7. He X, He L, Hannon GJ (2007) The guardian’s little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 67: 11099–11101. 8. Wiemer EA (2007) The role of microRNAs in cancer: no small matter. Eur J Cancer 43: 1529–1544. 9. Stallings RL (2009) MicroRNA involvement in the pathogenesis of neuroblas- toma: potential for microRNA mediated therapeutics. Curr Pharm Des 15: 456–462. 10. Stallings RL, Foley NH, Bray IM, Das S, Buckley PG (2011) MicroRNA and DNA methylation alterations mediating retinoic acid induced neuroblastoma cell differentiation. Semin Cancer Biol 21: 283–290. 11. Stallings RL, Foley NH, Bryan K, Buckley PG, Bray I (2010) Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets 14: 951–962. 12. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, et al. (2009) Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One 4: e7850. 13. Buckley PG, Alcock L, Bryan K, Bray I, Schulte JH, et al. (2010) Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res 16: 2971–2978. 14. Chen Y, Stallings RL (2007) Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 67: 976–983. 15. Lin RJ, Lin YC, Chen J, Kuo HH, Chen YY, et al. (2010) microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 70: 7841–7850. 16. Mestdagh P, Fredlund E, Pattyn F, Schulte JH, Muth D, et al. (2010) MYCN/c- MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene 29: 1394–1404. miRNA Expression Profiling of Murine Neuroblastoma Mouse miRNAs expressed in greater than 10 Table S1 samples. (XLSX) Table S3 human. (XLSX) Table S2 miRNAs differentially expressed in tumors compared to adrenals. (XLSX) mouse miRNAs homologue between mouse and Table S4 PCA loadings based on miRNA differentially expressed in human MNA compared to non-MNA. (XLSX) Table S5 PCA loadings based on miRNA differentially expressed in mouse tumors compared to adrenals. (XLSX) Author Contributions Conceived and designed the experiments: MT LC RLS. Performed the experiments: MT LV AH HW. Analyzed the data: MT KB. Contributed reagents/materials/analysis tools: LC. Wrote the paper: MT LV LC RLS. 17. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, et al. (2010) Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. Int J Cancer 127: 2374–2385. 18. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, et al. (2008) Antagomir- 17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 3: e2236. 19. Mestdagh P, Bostrom AK, Impens F, Fredlund E, Van Peer G, et al. (2011) The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol Cell 40: 762–773. 20. Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, et al. (2010) MicroRNA- 184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 9: 83. 21. Welch C, Chen Y, Stallings RL (2007) MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26: 5017–5022. 22. Foley NH, Bray I, Watters KM, Das S, Bryan K, et al. (2011) MicroRNAs 10a and 10b are potent inducers of neuroblastoma cell differentiation through targeting of nuclear receptor corepressor 2. Cell Death Differ 18: 1089–1098. 23. Bray I, Tivnan A, Bryan K, Foley NH, Watters KM, et al. (2011) MicroRNA- 542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett 303: 56–64. 24. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16: 2985–2995. 25. Chesler L, Goldenberg DD, Collins R, Grimmer M, Kim GE, et al. (2008) Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10: 1268–1274. 26. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, et al. (2007) Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67: 9435–9442. 27. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, et al. (2005) Temporal dissection of p53 function in vitro and in vivo. Nat Genet 37: 718–726. 28. Bell E, Premkumar R, Carr J, Lu X, Lovat PE, et al. (2006) The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage. Cell Cycle 5: 2639–2647. 29. Carr J, Bell E, Pearson AD, Kees UR, Beris H, et al. (2006) Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res 66: 2138–2145. 30. Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, et al. (2010) p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 70: 1377–1388. 31. Slack A, Lozano G, Shohet JM (2005) MDM2 as MYCN transcriptional target: implications for neuroblastoma pathogenesis. Cancer Lett 228: 21–27. 32. Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, et al. (2011) Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One 6: e19133. PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28356